ERYTHROPOIETIN STUDY
Feasibility and safety of erythropoietin (EPO) administration in patients with acute myocardial infarction (AMI) to improve cardiac function and remodelling.
Eastern Heart Clinic
20 participants
Jun 7, 2006
Interventional
Conditions
Summary
The purpose of this study is to test the feasibility and safety of intravenous erythropoietin (EPO) injections in patients with recent acute myocardial infarction to improve cardiac remodelling and cardiac function
Eligibility
Inclusion Criteria1
- Acute ST elevation myocardial infarction that are treated with primary angioplasty and stenting who have significant left ventricular (LV) impairment.
Exclusion Criteria1
- Multiple - but particularly major comorbidities.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Erythropoietin administration (10000units given as a one-off [single dose] intravenous bolus dose) within 24 hours of primary percutaneous intervention to treat patients with AMI. As this is a phase I safety study all subjects will receive open-label erythropoietin and there will be no control group or comparitor.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000238572